Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study
Background/objective Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that typically occurs in childhood/infancy and is associated with complications like extracutaneous atopic morbidity. Providing systemic treatment for pediatric AD patients with unmet comprehensive medical...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2025.2449589 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557905626628096 |
|---|---|
| author | Wu Liming Kamran Ali |
| author_facet | Wu Liming Kamran Ali |
| author_sort | Wu Liming |
| collection | DOAJ |
| description | Background/objective Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that typically occurs in childhood/infancy and is associated with complications like extracutaneous atopic morbidity. Providing systemic treatment for pediatric AD patients with unmet comprehensive medical needs remains challenging. We present a cohort study describing the efficacy and safety of dupilumab combined with topical calcineurin inhibitors (TCI) in children with moderate-to-severe atopic dermatitis under the age of 6 years.Methods A retrospective cohort study was conducted at a single center to analyze the use of dupilumab in combination with topical calcineurin inhibitors (TCI) in children aged 6 years and under moderate-to-severe AD that was inadequately controlled with topical therapy.Results Overall, 23 preschool children (mean [SD] age, 4.78 [1.278] years); 10 boys (43.5%) and 13 girls (56.5%) received 300 mg dupilumab every four weeks and TCI. The primary outcome, the average Eczema Area and Severity Index (EASI) percentage reduction from baseline, was −70.85%. Significant improvement was also observed in secondary outcomes: caregiver-reported Peak Pruritus numerical rating scale (P-NRS) (−77.73%), Body Surface Area (BSA) (−62.11%), and Investigators Global Assessment (IGA) (−36.23%) at week 16. A 1–2 grade decrease in IGA after 16 weeks of treatment was achieved by 91.3% of patients. There was a significant improvement in P-NRS and EASI scores from baseline to week 16. Injection-site reaction (one patient) and facial redness (two patients) were recorded. No severe drug-related adverse events were observed.Conclusion This study demonstrated that the combination of dupilumab and TCIs improved symptoms and quality of life in preschoolers with moderate-to-severe AD. |
| format | Article |
| id | doaj-art-1530a0c9e7264b23b0cba0274e0c636e |
| institution | Kabale University |
| issn | 0785-3890 1365-2060 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj-art-1530a0c9e7264b23b0cba0274e0c636e2025-01-06T09:16:27ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602025-12-0157110.1080/07853890.2025.2449589Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort studyWu Liming0Kamran Ali1Department of Dermatology, Affiliated Hangzhou First People’s Hospital, Westlake University School of Medicine, Hangzhou, ChinaDepartment of Dermatology, Affiliated Hangzhou First People’s Hospital, Westlake University School of Medicine, Hangzhou, ChinaBackground/objective Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that typically occurs in childhood/infancy and is associated with complications like extracutaneous atopic morbidity. Providing systemic treatment for pediatric AD patients with unmet comprehensive medical needs remains challenging. We present a cohort study describing the efficacy and safety of dupilumab combined with topical calcineurin inhibitors (TCI) in children with moderate-to-severe atopic dermatitis under the age of 6 years.Methods A retrospective cohort study was conducted at a single center to analyze the use of dupilumab in combination with topical calcineurin inhibitors (TCI) in children aged 6 years and under moderate-to-severe AD that was inadequately controlled with topical therapy.Results Overall, 23 preschool children (mean [SD] age, 4.78 [1.278] years); 10 boys (43.5%) and 13 girls (56.5%) received 300 mg dupilumab every four weeks and TCI. The primary outcome, the average Eczema Area and Severity Index (EASI) percentage reduction from baseline, was −70.85%. Significant improvement was also observed in secondary outcomes: caregiver-reported Peak Pruritus numerical rating scale (P-NRS) (−77.73%), Body Surface Area (BSA) (−62.11%), and Investigators Global Assessment (IGA) (−36.23%) at week 16. A 1–2 grade decrease in IGA after 16 weeks of treatment was achieved by 91.3% of patients. There was a significant improvement in P-NRS and EASI scores from baseline to week 16. Injection-site reaction (one patient) and facial redness (two patients) were recorded. No severe drug-related adverse events were observed.Conclusion This study demonstrated that the combination of dupilumab and TCIs improved symptoms and quality of life in preschoolers with moderate-to-severe AD.https://www.tandfonline.com/doi/10.1080/07853890.2025.2449589Dupilumabatopic dermatitispediatric ADpreschoolertopical calcineurin inhibitorsquality of life |
| spellingShingle | Wu Liming Kamran Ali Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study Annals of Medicine Dupilumab atopic dermatitis pediatric AD preschooler topical calcineurin inhibitors quality of life |
| title | Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study |
| title_full | Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study |
| title_fullStr | Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study |
| title_full_unstemmed | Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study |
| title_short | Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study |
| title_sort | efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis a retrospective cohort study |
| topic | Dupilumab atopic dermatitis pediatric AD preschooler topical calcineurin inhibitors quality of life |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2025.2449589 |
| work_keys_str_mv | AT wuliming efficacyofdupilumabwithconcomitanttopicalcalcineurininhibitorstreatmentforpreschoolchildrenwithatopicdermatitisaretrospectivecohortstudy AT kamranali efficacyofdupilumabwithconcomitanttopicalcalcineurininhibitorstreatmentforpreschoolchildrenwithatopicdermatitisaretrospectivecohortstudy |